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Previously, we demonstrated that nuclear localization of the Angiotensin II AT1A receptor was associated with the activation of transcription for
the COX-2 gene, PTGS-2. The hypothesis of the present study is that AT1AR internalization from the plasma membrane is a first step in the
nuclear localization of the endogenous AT1AR of rat aortic vascular smooth muscle cells and the resultant increase of COX-2 protein expression.
Angiotensin II produced both a time- and concentration-dependent increase in COX-2 protein expression in these cells. Treatment with sucrose or
phenylarsine oxide, inhibitors of receptor internalization, significantly inhibited AT1AR internalization and abolished the increase in COX-2
protein produced by Angiotensin II without affecting COX-2 expression on its own. Sucrose pre-treatment of rat aortic vascular smooth muscle
cells resulted in an increase in p42/44 and p38 activation, while phenylarsine oxide pre-treatment activated only p38 kinase without inhibiting
activation of p42/44 produced by Angiotensin II. These results demonstrate that inhibiting the internalization of the AT1AR results in a loss of
ability of Angiotensin II to increase the protein expression of COX-2, thus supporting previous work showing a relationship between AT1AR
nuclear localization and activation of COX-2 gene expression. Surprisingly, in contrast to other studies, the data also indicates that activation of
p42/44 and/or p38 does not correlate with the increased expression of COX-2.
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Angiotensin II (Ang II), a hormone product of the renin–
angiotensin system, stimulates both acute and chronic vascular
responses resulting in physiological and pathological sequelae.
Activation by Ang II of the AT1 receptor (R) produces G
protein-mediated intracellular signals resulting in several cel-
lular responses including activation of tyrosine kinases, nuclear
signaling, protein synthesis, including formation of extracel-
lular matrix proteins and vascular remodeling, events which are
central to development of atherosclerosis and hypertension [1].
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cellular regulated kinases (MAPKs) and signal transducers and
activators of transcription (STATs), translocate to the nucleus
upon Ang II activation. This activation can occur by both G
protein dependent and independent pathways and possibly
through transactivation of receptor tyrosine kinases [2–6].
However, an additional concept regarding GPCR signaling
and nuclear activation has been investigated. This is the concept
of nuclear trafficking of activated GPCRs, including the AT1R.
Since the original description in the early ‘80s of hepatic nuclear
Ang II binding sites [7], additional studies have shown nuclear
trafficking of AT1Rs [8–12]. Recently, through the utilization of
both wild-type and a specific site-directed mutant of the AT1AR,
we demonstrated that nuclear localization of the activated wild-
type receptor was associated with activation of the gene for
cyclooxygenase 2 (COX-2) PTGS-2 [13]. Suggesting that the
AT1AR contains a nuclear localization sequence and that nuclear
Fig. 1. Angiotensin II increases COX-2 protein expression in a time- and
concentration-dependent manner. A) Representative immunoblot of duplicate
samples of cell lysates frommonolayers of RASMC exposed to Ang II (100 nM)
for the indicated times. Detection of β-actin was used to control for loading and
transfer of proteins. B) Average values (±SE, n=3) of time-course studies
shown in (A). C) Average values (±SE, n=4) of concentration–response studies.
COX-2 expression induced by each concentration of Ang II was compared to that
seen in unstimulated cells. Equal amounts of cell lysates (10 μg) were used for
immunoblotting. (⁎pb0.05 vs. unstimulated cells, ANOVAwith Fishers PLSD.)
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the gene for COX-2. Questions remain as to the source, the
pathway and the mechanism for the trafficking of the receptor
to the nucleus.
The initial step in the pathway for intracellular trafficking
of activated GPCRs is internalization of the activated recep-
tor from the cell surface. Ligand-activated receptors initiate G
protein-mediated activation of GPCR kinases (GRKs), pro-
ducing phosphorylation of residues within the cytoplasmic tail
of the receptor with subsequent interaction of the receptor with
β-arrestins. This halts further activation of G proteins and
directs the receptor into clathrin-coated pits along the surface
of the membrane. The clathrin-coated pits are subsequently
“pinched-off” by the actions of dynamin, a membrane-bound
GTPase [14], thus initiating the intracellular trafficking of the
receptor.
Cyclooxygenase-2, an inducible enzyme responsible for me-
tabolizing arachidonic acid into prostaglandin G2 (PGG2), has
been implicated in not only normal kidney development but also
in mediating numerous pathologies ([15], for review). Ang II, via
the AT1R, enhances the expression level of COX-2 in severaltissues and organs including vascular smooth muscle [16]. Nu-
clear factor-κB (NF-κB) and several cytoplasmic kinases in-
cluding Pyk2, MEKK4 and p38 have been implicated in the
ability of Ang II to produce this effect in smooth muscle.
In the present study, we have used sucrose and phenylarsine
oxide, two agents known to inhibit clathrin-dependent receptor
endocytosis, to test the hypothesis that inhibiting the inter-
nalization of the activated AT1AR would inhibit the ability of
Ang II to increase the expression of the COX-2 protein.
2. Materials and methods
2.1. Cell culture
Rat aortic vascular smoothmuscle cells (RASMC)were prepared from isolated
segments of rat thoracic aorta as previously described [17]. Cells were maintained
in DMEMhigh glucose supplemented with 10% fetal bovine serum (FBS) and 1%
antibiotic/antimycotic/fungizone and used between passages 3 through 12. HEK-
293 cells (American Type Culture Collection) stably expressing a wild-type
AT1AR/Green Fluorescent Protein (AT1AR/GFP) construct were maintained as
previously described [13] using Ham's F12 media supplemented with 10% FBS,
1% antibiotic/antimycotic/fungizone and G418 (400 μg/ml). Cell culture media
and supplements were obtained from GIBCO-BRL (Grand Island, NY).
2.2. Radioligand binding assays
Binding studies employing [125I]-Ang II were performed as previously des-
cribed [13]. For receptor internalization studies, confluent monolayers of RASMC
were exposed to [125I]-Ang II (∼200,000 cpm,∼100 fmol) at 4 °C. Subsequently,
cells were either washed with cold saline buffer to remove unbound radioligand
and then solubilized in 0.1%SDS/0.1MNaOH (groupA, total receptors available),
or acid washed (150 mM NaCl, 50 mM glycine, pH 3.0 for 5 min), solubilized
and associated radioactivity counted (group B, non-specific binding), or washed
with cold saline to remove unbound [125I]-Ang II and then exposed to binding
buffer at 37 °C for 5 min to allow for internalization, and then acid washed to
remove surface bound radioligand, solubilized and associated radioactivity de-
termined (group C). The amount of internalized receptor was then determined as a
percentage from ([C−B]/ [A−B])×100.
2.3. Immunoblotting
Confluent monolayers of RASMCwere serum-deprived (0.1% FBS) for 24–
48 h. Cells, in cell culture media (6 well plates, COX-2 expression studies) or
Hank's Balanced Salt Solution (HBSS), 20 mM HEPES, pH 7.4 (12 well plates,
p42/44 ERK and p38 activation assays) were exposed to vehicle, sucrose
(0.4 M), phenylarsine oxide (5 μM), or losartan (10 μM) for 15 min 37 °C,
followed by addition of Ang II. At the end of the incubation period with Ang II,
the cells were washed 2× with ice-cold PBS followed by addition of RIPA
solubilization buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA,
1% NP-40, 0.25% Na-deoxycholate plus protease inhibitor cocktail I, 500 mM
AEBSF, 150 nM aprotinin, 1 mM E-64 and 1 mM leupeptin, Calbiochem).
Lysates (10–20 μg) were separated by SDS-PAGE (4–20% gradient), trans-
ferred to nitrocellulose and probed for the presence of the COX-2 protein using
a rabbit polyclonal antibody (1:200, Upstate, Lake Placid, NY), a mouse
monoclonal antibody to β-Actin (1:5000, Sigma-Aldrich, St. Louis, MO) or to
phosphorylated p42/44 ERK (phospho-p42/44), total p42/44 ERK, phosphory-
lated p38 or total p38 (1:2000, Cell Signaling Technology, Beverly, MA)
according to the manufacturers' directions. Blots were stripped of antibodies
between probing for phosphorylated and total proteins. Detection of protein
bands was performed by addition of CDP-Star reagent (New England Biolabs,
Ipswich, MA) and visualized by exposure of the nitrocellulose to radiographic
film (X-OMAT, Kodak). Quantitation of the visualized protein bands was
performed by densitometric scanning of the exposed radiographic film (Kodak
Molecular Imaging Software, Rochester, NY). The density ratio for phosphory-
lated protein to total protein was used as an indicator of kinase activation.
Fig. 2. Inhibition of AT1AR internalization by sucrose and by phenylarsine
oxide. Monolayers of RASMC were exposed to sucrose (0.4 M) or to pheny-
larsine oxide (5 μM) for 15 min prior to addition of [125I]-Ang II. Cells were
incubated on ice for 90 min followed by 5 min incubation at 37 °C. Cell
associated radioactivity was used as a marker for internalization of the AT1AR.
Percent internalization was calculated as described in Materials and methods.
Average values (±SE) from the indicated number (n) of studies are shown.
⁎pb0.05 vs. Control.
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HEK-293 cells stably expressing the wild-type AT1AR/GFP construct were
plated onto collagen-coated 25-mm glass cover slips in 6-well plates and
maintained in selection medium. Prior to study, cells were deprived of serum
(0.1% FBS) for 24–48 h. On the day of study, the medium was removed and the
cover slip was mounted into a thermo-regulated heating block at 37 °C (Olympus
America, Melville, NY) and HBSS (1 ml) added to the cells. Vehicle, sucrose
(0.4 M), or phenylarsine oxide (5 μM) was added to the cells. Angiotensin II
(100 nM) was added 15 min later. Microscopic images were acquired for a
subsequent 30 min by using an Olympus microscope UltraView LCI High
Resolution workstation (PerkinElmer Life Sciences, Boston, MA) equipped with
a laser scanning confocal unit (Omnichrome, Chino, CA), 15-mW krypton 3 line
laser head, and a UAPO 340 40× 1.35 or PlanAPO 60× 1.4 NA oil immersion
objective. GFP fluorescence was excited by using the 488-nm argon laser
emission line and collected using a standard fluorescein isothiocyanate filter set
(530±30 nm).
2.5. Statistics
Values shown are means±SE from the indicated number of studies (n) and
comparisons were made usingMicrosoft Excel data analysis package employing
ANOVAwith Fisher's post hoc t-test where indicated. Significance was tested at
the 95% level.Fig. 3. Confocal imaging of inhibition of AT1AR/GFP internalization by sucrose
and by phenylarsine oxide. HEK-293 cells stably expressing AT1AR/GFP were
pre-treated with either phenylarsine oxide (5 μM), sucrose (0.4 M), or buffer for
15 min prior to exposure to Ang II (100 nM, 37 °C) and prepared for imaging as
described in Materials and methods. Images shown were obtained 30 min after
exposure to Ang II. A) Buffer treated, unstimulated cells. B) Buffer treated, Ang
II stimulated cells, C) phenylarsine oxide/Ang II, and D) sucrose/Ang II
stimulated. Arrows indicate internalized receptor (B). Bar indicates scale of
10 μm. Representative of 3 similar studies.3. Results
3.1. Angiotensin II induction of COX-2 expression
Previous reports demonstrate increased expression of COX-2
in vascular smooth muscle cells exposed to Ang II [18,19]. In
our present study, we utilized immunoblotting to demonstrate
both a time- and concentration-dependent increase in COX-2
protein levels in RASMC exposed to Ang II (Fig. 1). Expression
of COX-2 was seen to be minimally detectable in serum-starved
RASMC. The level of protein increased approximately 2-fold
after 3 h exposure to Ang II (100 nM). All further studies
employed RASMC exposed to a concentration of Ang II of
100 nM for 3 h, a concentration and time demonstrating a
maximum increase in protein expression.3.2. Inhibition of AT1AR internalization
To test for the relationship between receptor internalization
and induction of COX-2 expression we first inhibited the initial
step of the internalization of ligand-activated GPCRs, namely
association of the plasma membrane-bound desensitized re-
ceptor with clathrin-coated pits. Hyperosmotic sucrose and
phenylarsine oxide, a tyrosine phosphatase inhibitor, have been
used previously to inhibit the formation of clathrin-coated pits
and as a consequence, internalization of activated GPCRs. We
chose to use these two compounds to inhibit AT1AR internaliza-
tion and to examine the effects of this inhibition on Ang II-
induced expression of COX-2. To ensure that these agents
effectively reduced internalization of the activated receptor,
we first tested their effects on internalization of the AT1AR
of RASMC through radioligand binding assays. Monolayers
of RASMC were exposed to either sucrose (0.4 M) or to
phenylarsine oxide (PAO, 5μM) as described and internalization
of the AT1AR was determined utilizing [
125I]-Ang II as a marker
for the internalized receptor. In Control, untreated RASMC
approximately 40% of the radioligand was found internalized
after 5 min of incubation. Pre-treatment of the cells with either
sucrose or with PAO significantly reduced the amount of in-
ternalized radioligand to approximately 20% and 10%, respec-
tively (Fig. 2).
A second method for evaluating the effectiveness of these
agents at inhibiting receptor internalization was to visually
examine AT1AR internalization in HEK-293 cells stably ex-
pressing the AT1AR/Green Fluorescent Protein (GFP) construct
[13]. Sub-confluent monolayers of AT1AR/GFP/HEK cells were
Fig. 4. Inhibition of Ang II-induced COX-2 expression in RASMC by inhibitors
of receptor internalization. RASMC were exposed to sucrose (0.4 M) or to
phenylarsine oxide (5 μM) for 15 min prior to exposure vehicle (−) or to Ang II
(100 nM, +) for 3 h. A) Representative immunoblot of COX-2 and β-actin
expression was performed as described. Detection of β-actin was performed on
the same blot and was used to correct for protein loading and transfer to
nitrocellulose. B) Summary of densitometric analysis of COX-2 protein
expression. Values shown are averages±SE from the indicated number of
studies (n). Average values from PAO alone and from sucrose alone are not
shown since there was no direct effect of these agents on COX-2 expression.
⁎pb0.05 vs. all other samples.
Fig. 5. Effect of internalization inhibitors on Ang II activation of p42/44 ERK in
RASMC.Monolayers of RASMCwere exposed to sucrose (0.4M), phenylarsine
oxide (5 μM, PAO) or to vehicle for 15 min followed by addition of Ang II
(100 nM). Five minutes later cells were lysed and prepared for immunodetection
of activated (phosphorylated) p42/44 ERK. A) Representative immunoblot
showing detection of phospho-p42/44 ERK (p-ERK) from Control, sucrose,
PAO and losartan (10 μM) pre-treated cells without (−) and with (+) subsequent
exposure to Ang II. Samples were run in duplicate and images shown were taken
from different lanes of the same immunoblot. Detection of total p42/44 ERK is
shown and is used to correct for protein loading and for transfer to nitrocellulose.
B) Average values (±SE) of p42/44 ERK phosphorylation for indicated samples
from the indicated (n) number of studies. ⁎pb0.05 vs. unstimulated cells.
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15 min, 37 °C followed by addition of Ang II (100 nM) for an
additional 30 min. Live cell imaging was performed as des-
cribed. Untreated cells demonstrated fluorescence predomi-
nately associated with the plasma membrane (Fig. 3A).
Untreated cells exposed to Ang II demonstrated internaliza-
tion of the AT1AR/GFP construct as indicated by fluorescent
“speckling” seen within the cytoplasm (Fig. 3B). Cells pre-
treated with PAO and then exposed to Ang II resulted in lack
of intracellular speckling indicative of a lack of receptor
internalization. Cell morphology in these samples demonstrated
a ruffling of the plasma membrane indicative of a cell response
to the addition of Ang II. In addition, dense fluorescent clusters
can be seen within the membrane suggesting the association
of activated receptors possibly within endosomal pits, sitting
within the membrane and prevented from clathrin-dependent
internalization by PAO (Fig. 3C). Lastly, pre-treatment with
sucrose and subsequent exposure to Ang II also resulted in a
lack of receptor internalization (Fig. 3D).
3.3. Effect of sucrose and PAO on Ang II-induced COX-2
expression
Both sucrose and PAO inhibited Ang II-induced AT1AR
internalization. To determine if these agents affected Ang II's
ability to increase the expression of COX-2, RASMC were
exposed to either vehicle, sucrose (0.4 M) or to PAO (5 μM) for
15 min prior to addition of Ang II (100 nM). Three hours later,
cells were lysed and prepared for detection of COX-2 protein
expression by immunoblotting. Ang II, as seen previously,produced approximately 3-fold increase in expression of COX-2
(Fig. 4). This effect was mediated by the AT1AR in that it was
blocked by the receptor antagonist losartan. Both sucrose and
PAO pre-treatment abolished the increase in COX-2 expression
caused by Ang II without having any effect on COX-2 ex-
pression on their own.
3.4. Effects of sucrose and PAO on Ang II-induced activation of
p42/44 ERK and p38
The intracellular kinases p42/44 (p42/44 ERK, a kinase me-
diating cell hypertrophy and hyperplasia) and p38 (a kinase ac-
tivated by oxidative stress) have been implicated as mediators in
the ability of Ang II to induce the expression of COX-2 in
RASMC [18–20]. Since sucrose and PAO blocked receptor
internalization and COX-2 expression initiated by Ang II, we
assessed whether these compounds would also inhibit p42/44
ERK and p38 kinase phosphorylation by Ang II. In untreated
cells, Ang II produced an approximately 2.5-fold increase in the
amount of phosphorylated p42/44 ERK (Fig. 5). Surprisingly,
treating the cells with sucrose (0.4 M) alone produced
phosphorylation of p42/44 ERK to a level similar to that of
Ang II. When cells pre-exposed to sucrose were subsequently
stimulated with Ang II, there was no further increase in activation
(Fig. 5). Cells pre-treated with PAO (5 μM) did not show p42/44
ERK phosphorylation nor did PAO inhibit the increase in p42/44
ERK phosphorylation produced by Ang II (Fig. 5).
Fig. 6. Effect of internalization inhibitors on Ang II activation of p38 in RASMC.
Monolayers of RASMC were exposed to sucrose (0.4 M), phenylarsine oxide
(5 μM, PAO) or to vehicle for 15 min followed by addition of Ang II (100 nM).
Five minutes later cells were lysed and prepared for immunodetection of
activated (phosphorylated) p38. A) Representative immunoblot showing
detection of phospho-p38 (p-p38) from Control, sucrose, PAO and losartan
(10 μM) pre-treated cells without (−) andwith (+) subsequent exposure to Ang II.
Detection of total p38 is shown and is used to correct for protein loading and for
transfer to nitrocellulose. B) Average values (±SE) of p38 activation for indicated
samples from the indicated (n) number of studies. ⁎pb0.05 vs. unstimulated
cells.
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similar to that seen for p42/44 ERK. Sucrose, on its own
produced an increase in p38 phosphorylation, an increase that
was augmented slightly by subsequent addition of Ang II. PAO,
unlike its effect on p42/44 ERK phosphorylation, tended to
produce an increase in p38 phosphorylation. Ang II further
increased the activation seen in cells pre-treated with PAO
(Fig. 6). The AT1AR antagonist, losartan, inhibited Ang II
activation of both p42/44 ERK and of p38 (Figs. 5A and 6A,
respectively).
4. Discussion
In the present study we examined the influence of clathrin-
dependent AT1AR internalization on the Ang II-induced ex-
pression of COX-2 in RASMC. We have demonstrated the
following: 1) Ang II increased the expression of COX-2 in both
a time- and concentration-dependent manner in RASMC. 2)
Both sucrose and phenylarsine oxide, inhibitors of clathrin-
dependent internalization, inhibited internalization of the
AT1AR. 3) Treatment with sucrose resulted in an increase in
both p42/44 ERK and p38 phosphorylation, while PAO only
increased activation of p38. 4) Treatment with PAO did not
inhibit the ability of Ang II to activate p42/44 ERK or p38. And
finally, treatment with sucrose or with PAO abolished the abi-
lity of Ang II to increase the protein expression of COX-2.
Trafficking of GPCRs as it relates to receptor desensitization
and recycling has long been a subject of investigation. Traf-
ficking as it pertains to signal-transduction is a subject gainingin interest. Many recent studies show that activated internalized
GPCRs such as the AT1AR, can act as a signaling scaffold
whereby intracellular signaling pathways can be amplified as
with activation of p42/44 ERK [21]. Included in the examina-
tion of GPCR trafficking and signal-transduction is the less
studied concept of nuclear signaling coupled to nuclear traf-
ficking of GPCRs. Several GPCRs have been described as
either residing in or trafficking to the nuclear area. A functional
nuclear AT1R was described in the early ‘80s [22]. More re-
cently, using the techniques of green fluorescent protein (GFP)-
tagged receptors and fluorescence and Confocal microscopy,
the apelin, bradykinin and AT1 receptors were seen to traffic to
the cell nucleus [23]. Previously, we demonstrated through the
use of GFP constructs of both a wild-type and a site-directed
mutant of the AT1AR not only AT1AR trafficking to the nucleus
but also that this trafficking was associated with an increase in
transcription for the COX-2 gene PTGS-2 [13]. The wild-type
receptor localized to the nucleus and activated PTGS-2 gene
transcription subsequent to stimulation while the site-directed
mutant [K307Q]AT1AR failed to localize to the nucleus and
failed to activate the PTGS-2 gene, thus associating AT1R
nuclear localization with COX-2 expression. Others have sug-
gested that the intracellular trafficking of the AT1AR acts as
an intracrine system to “deliver” Ang II to intracellular/nuclear
AT1Rs. This intracellular delivery of Ang II results in activation
of nuclear events including proliferation, activation of tran-
scription factors and protein synthesis [24–27].
Activation of cyclooxygenase (COX-1 and/or COX-2) is
responsible for a plethora of both physiological and pathologi-
cal responses. The activity of constitutive COX-1 results in
the generation of prostanoids utilized to maintain physiologic
homeostasis. Cyclooxygenase-2, an inducible enzyme respon-
sible for metabolizing arachidonic acid into prostaglandin G2
(PGG2), has been implicated in many pathologies including
pain, inflammation and cancer. In a vascular smooth muscle cell
culture model, Ang II induces the transcription for COX-2 via
involvement of nuclear factor-κB (NF-κB) and mediation of
several cytoplasmic kinases including Pyk2, MEKK4 and p38
[18,19,28]. Tumor necrosis factor-α (TNF-α) and Ang II ac-
tivation of vascular smooth muscle cell proliferation is de-
pendent upon the increased generation of prostanoids from
the increased expression of COX-2 [20]. Through the use of
pharmacological inhibitors, the increased expression of COX-2
was found to be dependent upon activation of p42/44 ERK,
while the proliferation was dependent upon COX-2 generated
thromboxane A2. Subsequently, the Ang II increased expression
of COX-2 was shown to be a result of increased mRNA stability
mediated by p42/44 ERK and p38 activation [18]. In that study,
Ang II-induced COX-2 expression was “significantly attenu-
ated” by treatment with inhibitors of p42/44 ERK and p38. In
contrast, Hu et al., found that the Ang II-induced COX-2 ex-
pression in human vascular smooth muscle cells was depen-
dent upon increased transcriptional activation dependent upon
NF-κB and did not involve activation of p38 [19].
In the present study, we also demonstrate both concentration-
and time-dependent increases in COX-2 protein expression with
maximum effects seen at a concentration and time similar to
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as the kinases p38 and p42/44 ERK, have been implicated in
Ang II-induced expression of COX-2. A relationship between
AT1AR internalization and expression of COX-2 has not been
examined. Hyperosmotic sucrose has been used extensively as
a tool for inhibiting the internalization of activated GPCRs.
Sucrose inhibits the internalization of receptors through its
ability to prevent the formation of the clathrin lattice sur-
rounding clathrin-coated pits [29]. Another agent known to
inhibit clathrin-coated pit formation is the tyrosine phosphatase
inhibitor phenylarsine oxide (PAO). PAO can exert multiple
effects on cell function, but when used at the concentrations
chosen for this study (5 μM), it blocks internalization of
receptors such as the activated AT1AR [30,31]. Through stu-
dies employing radioligand binding assays and laser scanning
confocal microscopy, we demonstrate that both sucrose and
PAO significantly inhibit the internalization of the AT1AR.
Despite blocking this internalization, intracellular signaling, i.e.
activation of p42/44 ERK, initiated by Ang II was not inhibi-
ted. The lack of inhibition of p42/44 ERK and p38 activation
despite inhibition of AT1AR internalization is not surprising
in light of the ability of the AT1AR to transactivate the EGF
receptor in vascular smooth muscle cells, a signaling event
independent of receptor internalization [3]. Sucrose pre-treat-
ment, on its own, resulted in significant increase in p42/44
phosphorylation, an increase that was not augmented by fur-
ther activation with Ang II. Activation of p42/44 ERK as a
consequence of hyperosmotic shock, such as that caused by
exposure to sucrose, has been demonstrated previously in
vascular smooth muscle [32].
As has been mentioned, others have shown a dependence
upon activation of p42/44 ERK and p38 in the ability of Ang II
to increase the expression of COX-2 in vascular smooth muscle
cells. In those previous studies pharmacological inhibition of
either p42/44 ERK or p38 significantly, but not totally, reduced
COX-2 expression. So, it is surprising to find that the phos-
phorylation of p42/44 ERK and p38 by sucrose and the
activation of p38 by PAO did not result in a corresponding
increase in COX-2 expression. Caution should be employed
when interpreting findings from the use of these pharmacolo-
gical agents in that receptor-independent activation of intracel-
lular signaling may occur. In fact, as is seen in the present study,
treatment with these agents completely abolished Ang II-in-
duced expression of COX-2 while not blocking Ang II effects
on p42/44 ERK and p38. This suggests that in rat vascular
smooth muscle that increased COX-2 protein expression ini-
tiated by Ang II may be the result of activation of two signal-
transduction pathways, one the classical G protein-coupled p42/
44 ERK pathway and a second pathway dependent upon the
intracellular trafficking of the AT1AR to the nuclear area, with
the intracellular trafficking to the nuclear area acting in con-
cert with the previously described concept of “scaffold”
activation of the p42/44 ERK pathway.
The present study suggests that internalization of activated
AT1AR may play a critical role in the ability of Ang II to initiate
specific nuclear events such as protein synthesis, including that
for cyclooxygenase 2, and that the nuclear localized activatedreceptor is derived from the plasma membrane. Questions
still exist as to the mechanism for this effect, is it related to
the receptor acting as the above mentioned delivery system
for Ang II, or is it possible that a portion of the receptor, i.e. the
C-terminal tail, is cleaved from the receptor as recently
described by Cook et al. [33] and subsequently traverses to
the nucleus to act as a nuclear transcriptional factor similar to
what has been described for the epidermal growth factor
receptor ErbB-2 [34, 35]. These and other factors related to the
relationship between intracellular trafficking of the AT1AR and
nuclear activation are areas of current investigation.
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